User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes

Novo Nordisk

Status: Active, not recruiting

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Treatments: Device: DuraTouch®

Study type: Observational

Funder types: Industry

Identifiers

NCT07052292

U1111-1316-4217 (Other Identifier)

NN1250-8353

Details and patient eligibility

About

This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.

Enrollment: 125 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• The decision to initiate treatment with DuraTouch® has been made by the participant/legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
• All needed signed consent(s) are obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

Exclusion criteria

• Previous participation in this study. Participation is defined as having given informed consent in this study.
• Mental incapacity (when no caregiver and LAR are assigned to the patient), unwillingness or language barriers precluding adequate understanding or cooperation.

Trial design

125 participants in 1 patient group

DuraTouch® (Insulin injection)

Description:

Participants will subcutaneously inject the insulin prescribed by the doctor using DuraTouch® according to routine clinical practice at the discretion of the treating physician.

Treatment:

Device: DuraTouch®